Brokerages expect that BioXcel Therapeutics Inc (NASDAQ:BTAI) will report earnings of ($0.67) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for BioXcel Therapeutics’ earnings, with estimates ranging from ($0.96) to ($0.50). BioXcel Therapeutics posted earnings of ($0.47) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 42.6%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 5th.
On average, analysts expect that BioXcel Therapeutics will report full year earnings of ($2.26) per share for the current year, with EPS estimates ranging from ($2.53) to ($2.12). For the next year, analysts anticipate that the company will post earnings of ($2.56) per share, with EPS estimates ranging from ($2.87) to ($2.00). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow BioXcel Therapeutics.
BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Thursday, November 14th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.02.
A number of research firms recently weighed in on BTAI. ValuEngine lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $30.00 target price (up from $25.00) on shares of BioXcel Therapeutics in a report on Wednesday, January 8th. SunTrust Banks began coverage on BioXcel Therapeutics in a report on Tuesday, November 12th. They set a “buy” rating and a $24.00 target price on the stock. BMO Capital Markets reissued a “positive” rating and set a $26.00 target price on shares of BioXcel Therapeutics in a report on Thursday. Finally, Canaccord Genuity boosted their target price on BioXcel Therapeutics from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $23.80.
Shares of BTAI stock traded down $0.78 during trading on Friday, reaching $16.67. 202,243 shares of the company’s stock were exchanged, compared to its average volume of 496,787. The company has a quick ratio of 5.04, a current ratio of 5.04 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $275.94 million, a PE ratio of -12.63 and a beta of 3.77. BioXcel Therapeutics has a twelve month low of $3.76 and a twelve month high of $19.89. The firm’s fifty day moving average price is $10.22 and its 200-day moving average price is $8.70.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. bought a new stake in shares of BioXcel Therapeutics during the 2nd quarter valued at $138,000. Bank of New York Mellon Corp purchased a new position in shares of BioXcel Therapeutics in the second quarter valued at $198,000. Renaissance Technologies LLC grew its position in shares of BioXcel Therapeutics by 59.8% in the second quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock valued at $785,000 after purchasing an additional 26,800 shares in the last quarter. Northern Trust Corp grew its position in shares of BioXcel Therapeutics by 247.7% in the second quarter. Northern Trust Corp now owns 43,822 shares of the company’s stock valued at $481,000 after purchasing an additional 31,218 shares in the last quarter. Finally, BlackRock Inc. grew its position in shares of BioXcel Therapeutics by 1,988.0% in the second quarter. BlackRock Inc. now owns 299,145 shares of the company’s stock valued at $3,278,000 after purchasing an additional 284,818 shares in the last quarter. Institutional investors and hedge funds own 23.19% of the company’s stock.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Story: Cryptocurrencies
Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.